Empaveli Archives -

Apellis’ chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may

Longer-term data raise prospects for Apellis’ pegcetacoplan

https://pharmaphorum.com/news/longer-term-data-raise-prospects-for-apellis-pegcetacoplan/

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in

EU gives narrower label to Apellis, Sobi’s PNH drug

https://pharmaphorum.com/news/eu-gives-narrower-label-to-apellis-sobis-pnh-drug/

Apellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major

Apellis reports mixed data with eye drug, but plans to file anyway

https://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

https://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/

Empaveli